OREX News Alert Orexigen Therapeutics (OREX) 5.98 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Orexigen Therapeutics (OREX) 5.98 $OREX

Novo Nordisk's Saxenda Gets FDA Nod, Launch in 1H15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:20PM CST
Novo Nordisk's (NVO) Saxenda received FDA approval as the first once-daily human glucagon-like peptide-1 analogue for chronic weight management.
OREX: 5.98 (+0.01), NVO: 43.80 (+1.08), ARNA: 3.57 (-0.01)

Novo Nordisk Enters Anti-Obesity Space With New FDA Approval
Spencer Osborne - at Seeking Alpha - Wed Dec 24, 6:46AM CST

ZFGN: 30.99 (+0.67), OREX: 5.98 (+0.01), NVO: 43.80 (+1.08), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)

FDA clears Novo Nordisk's weight loss drug Saxenda
AP - Tue Dec 23, 3:49PM CST
NEW YORK (AP) — The Food and Drug Administration has approved a Novo Nordisk diabetes drug as a treatment for obesity. It's the first injectable drug approved for weight loss.
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)

FDA clears Novo weight management drug
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 3:05PM CST

OREX: 5.98 (+0.01), NVO: 43.80 (+1.08), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)

Orexigen's Obesity Drug Mysimba Gets CHMP Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 5:10PM CST
The CHMP gave a positive opinion on the approval of Orexigen's (OREX) weight loss drug, Mysimba.
BIIB: 340.89 (+5.13), OREX: 5.98 (+0.01), AMGN: 160.67 (+3.15)

Contrave Prescriptions Still Rising In A Down Week
Clinically Sound Investor - at Seeking Alpha - Mon Dec 22, 2:47PM CST

OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)

Orexigen - Contrave Script Numbers Remain Impressive
Spencer Osborne - at Seeking Alpha - Mon Dec 22, 2:31PM CST

OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)

Belviq Scripts Dip - Lack Of T.V. Ads Will Impact Next Numbers
Spencer Osborne - at Seeking Alpha - Mon Dec 22, 2:27PM CST

OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)

Orexigen Retreats After Positive News In Europe: 3 Things To Watch For
Spencer Osborne - at Seeking Alpha - Mon Dec 22, 2:18PM CST

OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)

Orexigen Therapeutics (OREX) Stock: Weak On High Volume Today
at The Street - Mon Dec 22, 9:03AM CST
Trade-Ideas LLC identified Orexigen Therapeutics (OREX) as a weak on high relative volume candidate
OREX: 5.98 (+0.01)

Buying These 3 Stocks Is Like Making a Bet in a Burning House
George Budwell, The Motley Fool - Motley Fool - Mon Dec 22, 7:54AM CST
Source: Flickr user Mark Esau Bargain hunters are often attracted to beaten-down biotech stocks because they sometimes rebound in astonishing fashion. That said, it can be extremely difficult to separate the wheat from the chaff when mulling over...
OREX: 5.98 (+0.01), AZN: 70.44 (+0.26), VVUS: 2.99 (-0.02), AMGN: 160.67 (+3.15), AEGR: 21.59 (-0.27), SNY: 46.35 (+0.50), MNKD: 5.68 (+0.18)

New Obesity Drug Available Soon
Brian Orelli, The Motley Fool - Motley Fool - Sun Dec 21, 9:22PM CST
Europeans will have a new option for treating their obesity shortly. The Committee for Medicinal Products For Human Use, or CHMP, gave Orexigen 's Mysimba a positive recommendation. Orexigen will have to wait for the European Commission to adopt...
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)

Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.46 (+0.02), ASPX: 49.93 (-0.10), MDVN: 99.23 (+1.23), CYCC: 0.69 (+0.01), OPK: 9.63 (+0.21), NLNK: 39.08 (+1.36), JUNO: 39.99 (+2.71), REGN: 400.12 (+6.07), MYGN: 36.50 (+0.28), PFE: 31.42 (-0.03), IMGN: 5.90 (+0.13), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), BLRX: 1.68 (-0.01), OREX: 5.98 (+0.01), DVA: 76.06 (+0.07), BLCM: 19.30 (+0.18), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), MRK: 57.46 (+0.25), NVS: 93.91 (+0.66)

Arena And Vivus Investors Need To Grasp Implications Of Orexigen
Spencer Osborne - at Seeking Alpha - Fri Dec 19, 1:22PM CST

OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)

Contrave Wins Approval Recommendation In Europe
Spencer Osborne - at Seeking Alpha - Fri Dec 19, 10:53AM CST

OREX: 5.98 (+0.01)

Biotech Equities Technical Analysis -- Incyte, ZIOPHARM Oncology, Hemispherx Biopharma, Infinity Pharma, and Orexigen Therapeutics
PR Newswire - Fri Dec 19, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: Incyte Corporation (NASDAQ: INCY), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Hemispherx Biopharma Inc. (NYSE MKT: HEB), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), and Orexigen Therapeutics Inc. (NASDAQ: OREX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, December 18, 2014, rallied as the Dow Jones Industrial Average finished at 17,778.15, up 2.43% and the NASDAQ Composite closed at 4,748.40, up 2.24%. The S&P 500 finished the session 2.40% higher at 2,061.23. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 813.60, up 2.77%, with the index advancing 8.37% in the previous three months. Register for your complimentary reports on these five stocks at:
OREX: 5.98 (+0.01), ZIOP: 4.76 (+0.07), HEB: 0.22 (-0.02), INCY: 71.57 (+1.99), INFI: 16.65 (+0.37)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 8:11AM CST

KMX: 67.61 (-0.15), MOLG: 2.92 (+0.03), CERS: 6.49 (+0.29), OREX: 5.98 (+0.01), APP: 1.06 (+0.01), ISIS: 59.49 (+1.88), PIR: 15.33 (-0.11), BBRY: 10.67 (-0.13), IMGN: 5.90 (+0.13), FMD: 5.06 (unch), RHT: 70.92 (+0.47), PETX: 17.05 (+0.42), NVGN: 2.40 (-0.09), TRXC: 2.79 (+0.03), NQ: 4.32 (-0.36), FINL: 22.79 (+0.17), TNK: 4.74 (+0.04)

Europe advisory committee gives thumbs up to Orexigen obesity med
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 7:35AM CST

OREX: 5.98 (+0.01)

Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators
at The Street - Fri Dec 19, 7:25AM CST
European regulators recommended the approval of Orexigen Therapeutics weight-loss pill on Friday, opening a new commercial market opportunity closed off to the company's competitors.
OREX: 5.98 (+0.01), VVUS: 2.99 (-0.02), ARNA: 3.57 (-0.01)

Orexigen's Mysimba(TM) (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP Opinion Recommending Approval for Weight Management in the European Union
PR Newswire Europe - Fri Dec 19, 6:24AM CST
LA JOLLA, California, Dec. 19, 2014 /PRNewswire/ -- Orexigen Therapeutics announced today that the Committee for Medicinal Products For Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a centralized marketing authorization for Mysimba(TM) (naltrexone HCI / bupropion HCI prolonged release), as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (>=18 years) with an initial Body Mass Index (BMI) of >= 30 kg/m(2) (obese), or >= 27 kg/m(2) to Ee 30 kg/m(2) (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension).
OREX: 5.98 (+0.01)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 69

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 167

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 84

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 104

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 107

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 81

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 79

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 75

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading

Top 5 Most Recently Viewed Articles

Larry Chen's Transformative Journey in Automotive Photography

Updated Category News Views 460

Celebrating 20 Years of Automotive Photography Renowned automotive photographer Larry Chen presents his first-ever book titled Life at Shutter Speed: Two Decades of Larry Chen Photography. This extensive 400-page work features exceptional highlights from Chen's impressive career, along with captivating never-before-seen images. What’s Inside the Book? Life at Shutter...

Continue Reading
Kemper Corporation Achieves Record Stock High of $71.71

Updated Category News Views 157

Kemper Corporation Achieves New Stock Milestone Kemper Corporation (NYSE: KMPR) has reached an impressive milestone by achieving a remarkable 52-week high of $71.71. This achievement not only signifies a substantial uptrend for the diversified insurance holding but also reflects a commendable 67.95% increase in its stock value over the past year. The rising confidence...

Continue Reading
Rising Online Vaping Markets: A Challenge for Local Stores

Updated Category News Views 114

Challenges Faced by Local Convenience Stores in Quebec Local convenience stores in Quebec are confronting significant challenges due to the rise of online vaping sales. As these businesses grapple with a ban on flavored vapor products, introduced by Health Minister Christian Dubé, they are witnessing a shift in consumer behavior. This change has driven many customers to...

Continue Reading
Krispy Kreme Shareholders Invited to Join Class Action Lawsuit

Updated Category News Views 485

Krispy Kreme Investors: The Class Action Lawsuit Explained Krispy Kreme, Inc. (NASDAQ: DNUT) is facing a class action lawsuit that is generating significant attention among investors. This suit has been initiated by Robbins LLP following concerns about misleading statements made by the company's executives regarding its partnership with McDonald's. For anyone invested in...

Continue Reading
DexCom, Inc. Class Action Notice: Your Chance to Join Efforts

Updated Category News Views 62

Important Warning for DexCom, Inc. Shareholders Investors holding shares of DexCom, Inc. (NASDAQ: DXCM) should be aware of a critical opportunity to engage in a class action lawsuit. This notice emphasizes the essential details for shareholders who purchased shares during the specified class period. Your Participation Matters Shareholders are urged to reach out promptly...

Continue Reading